Display options
Cite
Ward A, Brogden RN, Heel RC, et al. Etretinate. A review of its pharmacological properties and therapeutic efficacy in psoriasis and other skin disorders. Drugs. 1983;26(1):9-43doi: 10.2165/00003495-198326010-00002.
Ward, A., Brogden, R. N., Heel, R. C., Speight, T. M., & Avery, G. S. (1983). Etretinate. A review of its pharmacological properties and therapeutic efficacy in psoriasis and other skin disorders. Drugs, 26(1), 9-43. https://doi.org/10.2165/00003495-198326010-00002
Ward, A, et al. "Etretinate. A review of its pharmacological properties and therapeutic efficacy in psoriasis and other skin disorders." Drugs vol. 26,1 (1983): 9-43. doi: https://doi.org/10.2165/00003495-198326010-00002
Ward A, Brogden RN, Heel RC, Speight TM, Avery GS. Etretinate. A review of its pharmacological properties and therapeutic efficacy in psoriasis and other skin disorders. Drugs. 1983 Jul;26(1):9-43. doi: 10.2165/00003495-198326010-00002. PMID: 6224672.
Copy Download .nbib Format: NLM
Share it on
Full text links
Springer

Drugs. 1983 Jul;26(1):9-43. doi: 10.2165/00003495-198326010-00002.

Etretinate. A review of its pharmacological properties and therapeutic efficacy in psoriasis and other skin disorders.

Drugs

A Ward, R N Brogden, R C Heel, T M Speight, G S Avery

PMID: 6224672 DOI: 10.2165/00003495-198326010-00002

Abstract

Etretinate (Ro 10-9359) is a new aromatic retinoic acid derivative for the treatment of severe psoriasis and other dyskeratoses. The pharmacological profile of etretinate suggests that it acts by normalizing pathological changes in epidermal and dermal skin, particularly inhibiting hyperkeratinization and cell differentiation, although its specific mode of action in different disorders remains to be elucidated. Etretinate is rapidly and presystemically metabolised to an active metabolite which appears in plasma at about the same time as parent drug. A 'deep' storage compartment with a very extended elimination half-life gives rise to detectable plasma levels of drug for at least 3 to 4 months after discontinuation of long term therapy. Studies suggest that etretinate at an initial dose of 1 mg/kg/day, reducible during maintenance therapy, is an effective alternative to PUVA and other conventional therapy in severe psoriasis. Its greatest immediate value is in the control of eruptive and treatment-resistant psoriasis, and in its potential for use in combination with other therapy to improve the response. In Darier's disease it appears to be the treatment of choice, and preliminary studies also suggest its usefulness in ichthyosis, and most other dyskeratoses and possibly in basal cell carcinoma. Side effects affecting the mucocutaneous system occur in nearly all patients, but rarely lead to drug withdrawal. When withdrawal does become necessary, the primary reason is usually hair loss. A few paradoxical observations of raised and lowered liver enzyme levels have been reported, and also a few cases of suspected liver damage. Etretinate is strictly contraindicated in women of child-bearing potential due to its severe teratogenic properties.

Cited by

References

  1. Eur J Cancer. 1981 Jan;17(1):35-42 - PubMed
  2. Acta Derm Venereol. 1980;60(5):461-2 - PubMed
  3. Br J Dermatol. 1978 Jun;98(6):681-4 - PubMed
  4. Hautarzt. 1981 Mar;32(3):119-25 - PubMed
  5. Dermatologica. 1981;162(4):236-42 - PubMed
  6. Dermatologica. 1982 Mar;164(3):209-16 - PubMed
  7. Br J Dermatol. 1980 Feb;102(2):195-202 - PubMed
  8. HNO. 1982 Aug;30(8):290-2 - PubMed
  9. Derm Beruf Umwelt. 1978;26(3):88-90 - PubMed
  10. Dermatologica. 1982 Sep;165(3):204-7 - PubMed
  11. Dermatologica. 1978;157 Suppl 1:38-44 - PubMed
  12. J Am Acad Dermatol. 1982 Apr;6(4 Pt 2 Suppl):760-5 - PubMed
  13. J Am Acad Dermatol. 1982 Apr;6(4 Pt 2 Suppl):746-50 - PubMed
  14. Z Hautkr. 1979 Jan 1;54(1):19-23 - PubMed
  15. Dermatologica. 1978;157(3):171-80 - PubMed
  16. Eur J Cancer. 1977 Aug;13(8):831-8 - PubMed
  17. Arch Dermatol Res. 1979 Mar 31;264(2):169-77 - PubMed
  18. Arch Dermatol. 1982 Feb;118(2):97-100 - PubMed
  19. Br J Dermatol. 1980 Nov;103(5):483-7 - PubMed
  20. Br J Dermatol. 1981 Sep;105(3):267-72 - PubMed
  21. Australas J Dermatol. 1980 Aug;21(2):76-8 - PubMed
  22. Lancet. 1982 Feb 13;1(8268):364-5 - PubMed
  23. Dermatologica. 1979;158(1):60-4 - PubMed
  24. Br J Dermatol. 1981 Jun;104(6):667-73 - PubMed
  25. Cancer Res. 1978 Mar;38(3):771-5 - PubMed
  26. Acta Derm Venereol. 1981;61(3):264-7 - PubMed
  27. Arch Dermatol Res. 1981;271(1):29-40 - PubMed
  28. Z Hautkr. 1978 Jul 15;53(14):494-504 - PubMed
  29. Dermatologica. 1978;157 Suppl 1:32-7 - PubMed
  30. Dermatologica. 1980;160(1):69-71 - PubMed
  31. Dermatologica. 1980;161(5):305-14 - PubMed
  32. Br J Dermatol. 1981 Jun;104(6):675-9 - PubMed
  33. Dermatologica. 1980;160(5):328-36 - PubMed
  34. Br J Dermatol. 1982 Jan;106(1):77-80 - PubMed
  35. Lancet. 1981 Dec 12;2(8259):1348-9 - PubMed
  36. Br J Dermatol. 1979 Jul;101 Suppl 17:38-40 - PubMed
  37. Arch Dermatol Res. 1980;267(2):153-9 - PubMed
  38. Dermatologica. 1979;159(1):62-70 - PubMed
  39. Br J Dermatol. 1981 Aug;105(2):201-5 - PubMed
  40. Arch Dermatol. 1981 Oct;117(10):611-9 - PubMed
  41. Dermatologica. 1981;162(5):404-13 - PubMed
  42. Br J Dermatol. 1978 Nov;99(5):561-8 - PubMed
  43. Z Hautkr. 1980 Jan 15;55(2):68-78 - PubMed
  44. Dermatologica. 1982 Aug;165(2):123-30 - PubMed
  45. J Natl Cancer Inst. 1977 Apr;58(4):923-30 - PubMed
  46. Arch Dermatol. 1982 Sep;118(9):660-2 - PubMed
  47. Arch Dermatol Res. 1982;272(1-2):147-9 - PubMed
  48. Boll Ist Sieroter Milan. 1982 May;61(2):112-5 - PubMed
  49. Dermatologica. 1980;161(3):179-82 - PubMed
  50. Arch Dermatol. 1981 Nov;117(11):749-50 - PubMed
  51. Experientia. 1978 Sep 15;34(9):1105-19 - PubMed
  52. J Natl Cancer Inst. 1977 May;58(5):1365-71 - PubMed
  53. Br J Dermatol. 1980 Feb;102(2):213-4 - PubMed
  54. Acta Derm Venereol. 1981;61(6):535-42 - PubMed
  55. Schweiz Med Wochenschr. 1977 Feb 5;107(5):144-7 - PubMed
  56. J Am Acad Dermatol. 1983 Jan;8(1):95-102 - PubMed
  57. Ann N Y Acad Sci. 1981 Feb 27;359:54-67 - PubMed
  58. Nature. 1979 Mar 8;278(5700):180-2 - PubMed
  59. Br J Dermatol. 1982 Dec;107(6):681-5 - PubMed
  60. Br J Cancer. 1976 Sep;34(3):239-48 - PubMed
  61. Mutat Res. 1978 Nov;58(2-3):317-20 - PubMed
  62. Actas Dermosifiliogr. 1980 Jul-Aug;71(7-8):293-6 - PubMed
  63. Acta Derm Venereol. 1979;59(3):241-4 - PubMed
  64. Cancer Res. 1976 Mar;36(3):964-72 - PubMed
  65. Ned Tijdschr Geneeskd. 1980 Aug 2;124(31):1286-90 - PubMed
  66. Intervirology. 1980;14(5-6):321-5 - PubMed
  67. Br J Dermatol. 1981 Mar;104(3):325-32 - PubMed
  68. Cancer. 1980 Nov 15;46(10):2203-9 - PubMed
  69. Ann Acad Med Singapore. 1983 Jan;12(1):45-51 - PubMed
  70. Cancer Res. 1979 Feb;39(2 Pt 1):419-25 - PubMed
  71. Dermatologica. 1978;157 Suppl 1:26-31 - PubMed
  72. Br J Dermatol. 1980 Feb;102(2):203-12 - PubMed
  73. Schweiz Med Wochenschr. 1979 Dec 15;109(48):1912-4 - PubMed
  74. Ann Dermatol Venereol. 1981;108(2):145-9 - PubMed
  75. Schweiz Med Wochenschr. 1979 Dec 15;109(48):1921-5 - PubMed
  76. Schweiz Med Wochenschr. 1979 Dec 15;109(48):1914-20 - PubMed
  77. Hautarzt. 1979 Mar;30(3):161-3 - PubMed
  78. Dermatologica. 1978;157 Suppl 1:19-25 - PubMed
  79. Calcif Tissue Int. 1981;33(3):249-54 - PubMed
  80. Dermatologica. 1981;163(2):164-8 - PubMed
  81. Ann Dermatol Venereol. 1978 May;105(5):465-8 - PubMed
  82. Arch Dermatol. 1981 Apr;117(4):225-8 - PubMed
  83. Cancer Treat Rep. 1982 Jun;66(6):1375-80 - PubMed
  84. Dermatologica. 1978;157 Suppl 1:60-3 - PubMed
  85. Eur J Cancer. 1975 Oct;11(10):721-4 - PubMed
  86. Dermatologica. 1978;157(4):238-44 - PubMed
  87. Arch Dermatol Res. 1982;272(1-2):37-47 - PubMed
  88. Wien Klin Wochenschr. 1979 Mar 2;91(5):161-4 - PubMed
  89. Br J Dermatol. 1982 Feb;106(2):141-52 - PubMed
  90. Helv Chim Acta. 1977 Nov 2;60(7):2309-25 - PubMed
  91. Dermatologica. 1980;160(6):405-8 - PubMed
  92. Cancer Res. 1978 Mar;38(3):793-801 - PubMed
  93. Br J Cancer. 1977 Jan;35(1):115-9 - PubMed
  94. Cutis. 1980 Mar;25(3):300-4 - PubMed
  95. N Z Med J. 1981 Oct 28;94(694):307-8 - PubMed
  96. Arch Dermatol. 1982 Aug;118(8):559-62 - PubMed
  97. Arch Dermatol Res. 1979 May 4;264(3):331-7 - PubMed
  98. Dermatologica. 1978;157 Suppl 1:5-10 - PubMed
  99. Z Hautkr. 1982 Sep 1;57(17):1255-67 - PubMed
  100. Cancer Res. 1979 Oct;39(10):4055-7 - PubMed
  101. J Am Acad Dermatol. 1982 Apr;6(4 Pt 2 Suppl):652-9 - PubMed
  102. J Am Acad Dermatol. 1982 Apr;6(4 Pt 2 Suppl):699-704 - PubMed
  103. Cancer Res. 1980 Jul;40(7):2194-6 - PubMed
  104. Acta Derm Venereol. 1982;62(4):361-4 - PubMed
  105. Ann Dermatol Syphiligr (Paris). 1976;103(5-6):619-20 - PubMed
  106. Br J Dermatol. 1982 Aug;107(2):251-2 - PubMed
  107. Dtsch Med Wochenschr. 1979 Mar 30;104(13):473-7 - PubMed
  108. Proc Soc Exp Biol Med. 1979 Oct;162(1):229-34 - PubMed
  109. Arzneimittelforschung. 1978;28(1):49-51 - PubMed
  110. Acta Derm Venereol. 1982;62(2):162-4 - PubMed
  111. Photochem Photobiol. 1979 Mar;29(3):531-7 - PubMed
  112. Br J Dermatol. 1978 Sep;99(3):319-24 - PubMed
  113. Ann Dermatol Venereol. 1978 Oct;105(10):807-11 - PubMed
  114. J Cutan Pathol. 1982 Jun;9(3):175-88 - PubMed
  115. Z Hautkr. 1979 Oct 1;54(19):873-16 - PubMed
  116. Experientia. 1974 Oct 15;30(10):1198-200 - PubMed
  117. Dtsch Zahnarztl Z. 1980 May;35(5):554-8 - PubMed
  118. J Invest Dermatol. 1978 Apr;70(4):178-82 - PubMed
  119. Z Hautkr. 1982 Sep 1;57(17):1247-54 - PubMed
  120. Acta Derm Venereol Suppl (Stockh). 1979;59(85):133-6 - PubMed
  121. Dermatologica. 1980;160(4):270-4 - PubMed
  122. Arch Dermatol Res. 1979 May 4;264(3):365-7 - PubMed
  123. Cancer Treat Rep. 1976 Nov;60(11):1647-53 - PubMed
  124. J Cancer Res Clin Oncol. 1979 Feb 19;93(2):149-60 - PubMed
  125. Dermatologica. 1981;162(2):124-36 - PubMed
  126. J Am Acad Dermatol. 1982 Apr;6(4 Pt 2 Suppl):683-7 - PubMed

Substances

MeSH terms

Publication Types

LinkOut - more resources